Introduction
Bruton’s tyrosine kinase (BTK) is at the core of present day treatment in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) which in turn is redefining first line and relapsed disease management. In terms of second-generation BTK inhibitors, zanubrutinib has been the focus for its efficacy, safety, and long-term disease control.
In the Phase 3 SEQUOIA study, which is turned to as the preeminent source of comparative evidence,
